TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
TYK Medicines, Inc. Class H ( (HK:2410) ) has shared an announcement.
TYK Medicines, Inc announced that its innovative drug Asandeutertinib has demonstrated significant efficacy in treating EGFR-mutant NSCLC patients with brain metastases, according to interim results from the ESAONA pivotal study presented at the 2025 World Conference on Lung Cancer. The study showed that Asandeutertinib had a higher intracranial objective response rate compared to osimertinib, indicating its potential as a new first-line treatment option. Despite some treatment-related adverse events, the drug’s promising results highlight its potential impact on the treatment landscape for NSCLC, offering hope for improved patient outcomes.
The most recent analyst rating on (HK:2410) stock is a Buy with a HK$31.60 price target. To see the full list of analyst forecasts on TYK Medicines, Inc. Class H stock, see the HK:2410 Stock Forecast page.
More about TYK Medicines, Inc. Class H
TYK Medicines, Inc is a pharmaceutical company based in China, specializing in the development of innovative drugs targeting EGFR mutations, particularly for non-small cell lung cancer (NSCLC) with brain metastases.
Average Trading Volume: 3,617,913
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$6.35B
See more data about 2410 stock on TipRanks’ Stock Analysis page.